Physician

Antonio Moran, M.D.

According to 2025 Medicare claims, Antonio Moran, M.D. (NPI: 1396735908) practices hematology/oncology in the Brunswick-St. Simons, GA market, with the plurality of this provider's patient population coming from Glynn, GA. This provider's primary affiliated billing organization is AMERICAN ONCOLOGY PARTNERS PA (NPI: 1265929723; TIN: 824681345) and primary practice location at 31525-7930.

Moran's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 549 traditional Medicare patients, billed 169,581 HCPCS/CPT codes, and received $2,886,169 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 2,979 prescription claims across 440 beneficiaries totaling $5,618,044 in drug costs, led by Revlimid (Lenalidomide). 2023 DME data shows 11 claims. Open Payments data shows 201 records totaling $4,909. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $230,816 to $2,886,169. Similarly, Part D prescription costs have risen steadily, from $1,762,392 to $5,618,044. In contrast, DME billing represents a smaller volume and fell sharply in recent years, from $10,575 to $2,301.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	622	6,984	$230,816
2016	575	5,847	$182,544
2017	584	6,396	$193,549
2018	535	5,626	$170,930
2019	505	4,833	$156,059
2020	420	47,857	$747,323
2021	475	141,756	$2,485,630
2022	486	147,351	$2,284,882
2023	499	170,587	$2,959,560
2024	549	169,581	$2,886,169

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	392	4,580	$1,762,392
2016	346	3,952	$2,367,348
2017	340	3,544	$2,978,338
2018	309	2,836	$2,904,810
2019	305	2,591	$2,958,576
2020	303	2,339	$3,396,596
2021	333	1,981	$3,109,351
2022	301	2,040	$3,770,716
2023	371	2,386	$3,464,658
2024	440	2,979	$5,618,044

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	175	$32,344
2016	N/R	58	$38,627
2017	11	59	$8,869
2018	N/R	28	$14,604
2019	24	60	$16,752
2020	N/R	109	$55,558
2021	N/R	80	$82,881
2022	N/R	39	$70,698
2023	N/R	11	$116
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	223	375	$91
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	410	832	$59
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	114	128	$12
36415	Insertion of needle into vein for collection of blood sample	499	1,661	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	500	1,835	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	56	1,484	$975,965
Imbruvica	Ibrutinib	53	1,544	$791,677
Ojjaara	Momelotinib Dihydrochloride	13	390	$343,309
Oxbryta	Voxelotor	26	780	$316,053
Jakafi	Ruxolitinib Phosphate	18	540	$314,492

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	201	$4,909	PFIZER INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Antonio Moran, M.D.?

Tedicare shows public-source Medicare data for Antonio Moran, M.D. (NPI 1396735908), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Antonio Moran, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Antonio Moran, M.D.?

Antonio Moran, M.D. is linked to AMERICAN ONCOLOGY PARTNERS PA (billing NPI 1265929723) in the available physician profile data.

Does Antonio Moran, M.D. have Open Payments data?

Antonio Moran, M.D. has 201 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.